In the latest trading session, GSK (GSK) closed at $37.10, marking a +1.23% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 0.39%.
Prior to today's trading, shares of the drug developer had gained 0.27% over the past month. This has...
Buy volume at resistance at this point in the falling channel should help propel the price to an initial measured target if $47 which would be thr breakout point of an even bigger bullish macro setup.
The PEAD projected a bullish outlook for GSK after a negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 80%.
Using longer term Auction Market Theory to construct longer term meaningful #VolumeProfiles can sometimes provide exceptional risk reward setups.
One has just popped up in GSK according to my read anyway.
Now price has returned into the longer term Value Area there's a very good chance price will return at least to the Point of Control (or even to the top of...
Great reward to risk in this weekly chart setup in $GSK, worth a shot, you can probably play it with options to not allocate too much capital in this idea and have limited downside risk. An ITM put spread or some kind of Iron Butterfly OTM can both reap the passage of time profiting from Theta dropping and also give a positive reward to risk if carefully...
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines,...
This is a low risk high reward gem.
90,000 employees is too many, look for a lay-off announcement to drive down price allowing for an ideal entry at $30.00
GSK technically at Jan 1992 Support/Resistance level.
On news of the Zantac issue.
This presents what could be a descending triangle pattern.
Will they be able to walk away from this horrible situation (for those that have consumed the original Zantac there are no words to describe)?
GlaxoSmithKlein (GSK) just formed a Death Cross on the 1D time-frame, which is when the 1D MA50 (blue trend-line) crosses below the 1D MA200 (orange trend-line). This is technically a bearish pattern but last time it formed (March 24 2020) was exactly on the bottom of the COVID crash and the price recovered rapidly.
That was of course in the aftermath of the...
